螺内酯治疗充血性心力衰竭的临床观察

刘娜

（渭南市第一医院心血管神经内科，陕西 渭南，714000）

浏览次数：84次 下载次数：300次

摘要：

目的 探讨螺内酯治疗充血性心力衰竭的临床效果。方法 将我院2015年6月至2016年6月收治的充血性心力衰竭患者106例作为研究对象，随机分为研究组和对照组，各53例。对照组患者给予常规抗心衰治疗，研究组患者在对照组治疗的基础上给予60 mg/d螺内酯进行治疗，观察两组患者的临床疗效。结果 治疗前两组患者各项指标比较均无显著差异（P>0.05），治疗后两组患者SI、LVMAI 没有发生明显变化，HR、PASP、LVEF、LVEDVI、LVESVI 及BNP相较于治疗前都明显降低（P<0.05）， 其中治疗后LVEDVI、LVESVI 及BNP指标水平组间比较，差异具有统计学意义（P<0.05）。结论 螺内酯治疗充血性心衰临床效果显著，副作用少，安全性高，价格低廉，可推广使用。

关键词：充血性心力衰竭；螺内酯；副作用

中图分类号：R541.6文献标志码：A文章编号：2096-1413(2016)27-0023-02

Clinical observation of spironolactone in the treatment of congestive heart failure
LIU Na
(Department of Cardiovascular Neurology Medicine, the First Hospital of Weinan, Weinan 714000, China)

ABSTRACT: Objective To investigate the clinical effect of spironolactone in the treatment of congestive heart failure. Methods One hundred and six patients with congestive heart failure in our hospital from June 2015 to June 2016 were selected as the research objects, and randomly divided into study group and control group, with 53 cases in each group. The control group was given conventional anti-heart failure therapy, and the study group received spironolactone 60 mg/d on the basis of the control group, the clinical efficacy of the two groups were observed. Results There was no significant difference of indicators in the two groups before treatment (P>0.05); after treatment, the SI and LVMAI of the two groups were not significantly changed (P跃0.05), but HR, PASP, LVEF, LVEDVI, LVESVI and BNP were significantly lower than those before treatment (P<0.05), and the difference of LVEDVI, LVESVI and BNP between the two groups after treatment were significant (P<0.05). Conclusion Spironolactone has obvious effect in the treatment of congestive heart failure, with few side effect, higher safety and lower price, which can be widely used.
KEYWORDS: congestive heart failure; spironolactone; side effect

参考文献：
[1] 陆备军.盐酸贝那普利联合螺内酯治疗慢性心力衰竭的疗效观察 [J].中国药房,2012,6(16):1488-1489.
[2] 胡远江.赖诺普利联合螺内酯治疗慢性充血性心力衰竭的疗效观察[J].中国药房,2012,3(12):1114-1115.
[3] 高志芳.美托洛尔联合依那普利、螺内酯治疗慢性心力衰竭的临床观察[J].中国实用医药,2011,6(21):183-184.
[4] 罗红雨.醛固酮拮抗剂螺内酯治疗慢性心力衰竭的临床观察[J].深圳中西医结合杂志,2015,25(8):68-70.
[5] 祝亚文.卡维地洛联合螺内酯治疗老年慢性心力衰竭的疗效观察[J].河北医药,2014(23):3593-3594.
[6] 马文辉,张英.替米沙坦联合螺内酯治疗充血性心力衰竭的临床研究[J].基层医学论坛,2013,17(34):4515-4517.
[7] 张冰.螺内酯与贝那普利联用方案治疗慢性充血性心力衰竭的临床疗效观察[J].中国伤残医学,2014,22(6):142-143.
[8] 张炜.卡维地洛与螺内酯联合应用治疗72例充血性心力衰竭的临床评价[J].航空航天医学杂志,2015,26(2):214-215.
[9] 王利亚.小剂量螺内酯治疗慢性充血性心力衰竭的短期疗效[J].中国医药导刊,2011,13(8):1363-1364.
[10] 陈少伟,周贻.卡维地洛与螺内酯联合治疗高龄慢性心力衰竭患者的疗效及安全性分析[J].中外医疗,2012,31(26):33-34.